These reverted SAP+ CD8+ T cells in XLP patients could respond to EBV and kill-EBV infected B cells, suggesting they were able to provide protective immunity against ongoing EBV infection (60). This evidence concerns the gene SH2D1A and X-linked lymphoproliferative disease.